dr mike israetel tirzepatide Dr. Israetel's Cutting Diet: Macros, Cardio & Strategy – RP Strength #335 ‒ The science of

[DOI] [PubMed] [Google Scholar] 128.Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

Key Health Benefits Beyond Diabetes and Weight Loss a) Cardiovascular Health Clinical trials show GLP-1 drugs lower risks of heart attacks, strokes, and cardiac deaths by improving cholesterol and reducing artery inflammation

Retatrutides ~144-hour half-life and tirzepatides ~120-hour half-life both support a single weekly subcutaneous dose, the schedule used in every registrational trial

The mean change from baseline in WRSSM total score at week 104 was 0.26 (SD = 0.71) in the semaglutide 2.4 mg group and 0.12 (SD = 0.68) in the placebo group

Patients typically report feeling fuller for longer periods and experiencing fewer food cravings